Avant-propos: Itinéraire des stratégies thérapeutiques du diabète de type 2

Nowadays, all organizations recommend maintaining the glycemic control within a reasonable range and lowering HbA1c levels to approximately 7% or less in order to prevent the development and progression of both micro- and macrovascular complications. To attain such goals, the treatment should be reinforced as soon as possible when the patient's individualized targets are not correctly achieved. For that reason, treatment escalation is a common feature throughout the time course of T2D. During the last past few years, our antidiabetic armamentarium has been enriched by the marketing of new drugs that permit better achievement of diabetic control in terms of efficacy and safety. These updated treatments and strategies were addressed during a meeting organized by the « Moroccan Association of the Physicians graduated in diabetology, nutrition and therapeutic education (ADN) » and held in Fez (Morocco), at the Faculty of Medicine and Pharmacy, from October 15 to 17, 2015. The data presented at this meeting are herein published as a series of articles describing the stepwise therapeutic itinerary of T2D across its continuum.